Apotex gets BBB (low) rating, revises credit deal with $1.2B facility

Apotex Health Corp. (TSX: APTX) announced the completion of an amended and restated credit agreement after receiving an inaugural BBB (low) investment-grade issuer rating from Morningstar DBRS, according to a press release dated July 16, 2026.

The amended credit agreement includes updated pricing and fees that reflect the new investment-grade rating, resulting in lower borrowing costs for the Toronto-based pharmaceutical company. The agreement also provides covenants offering greater operational flexibility.

The credit facility includes term loan facilities and a revolving credit facility with a total capacity of $1.2 billion. The Bank of Nova Scotia serves as administrative agent, with The Bank of Nova Scotia, RBC Capital Markets, and TD Securities acting as joint lead arrangers and joint bookrunners for the syndicate of lenders.

"This amendment to our credit facility represents an important milestone in our continued progression as a public company," said Brian McClelland, CFO of Apotex. "Achieving investment-grade financing terms reflects the strength of our business, balance sheet and cash flow profile."

You May Also Be Interested In

• Mattel and WWE to launch Lucha Libre AAA action figures in 2027
• AMD launches Helios rack-scale AI system with broad new product lineup
• CBIZ launches pooled employer plan for middle-market businesses